CardioNet, Inc. Appoints Anthony J. Conti to Its Board of Directors
May 10 2012 - 4:10PM
Business Wire
CardioNet, Inc. (NASDAQ:BEAT), a leading wireless medical
technology company with an initial focus on the diagnosis and
monitoring of cardiac arrhythmias, announced today that Anthony J.
Conti has joined the CardioNet Board of Directors and will serve as
the Chairman of its Audit Committee. Mr. Conti is an esteemed
leader whose illustrious career includes 37 years with
PricewaterhouseCoopers before his retirement in 2009. Mr. Conti
replaces Kirk Gorman, who will continue to serve as the Company’s
Chairman of the Board.
“I am extremely pleased to announce the appointment of Anthony
J. Conti to the CardioNet Board of Directors,” noted Joseph H.
Capper, CEO of CardioNet, Inc. “Mr. Conti’s superior leadership and
financial expertise will serve as valuable assets to the CardioNet
Board. We look forward to his contribution as we continue to
execute on our strategic initiatives.”
Mr. Conti joined Coopers and Lybrand in 1973, and served a wide
range of industrial, technology, utility and health services
clients. Mr. Conti held a number of leadership roles with Coopers
and Lybrand, and later with PricewaterhouseCoopers, after its
merger with Price Waterhouse in 1998. He presently serves as the
Chairman of the Audit Committee for Ametek, Inc., an electronic
instrument and electromechanical device company.
Mr. Conti’s professional merits are complemented by his strong
commitment to serving his community. Mr. Conti served as Chairman
of the Board of the World Affairs Council of Philadelphia until
December of 2011, and now serves as Chairman Emeritus. He also
served as a Member of the Board and Executive Committee of the
United Way of Southeastern Pennsylvania.
Mr. Conti holds a Bachelors of Arts degree in Economics from St.
Joseph's University and a Masters of Business Administration from
Temple University.
About CardioNet
CardioNet is the leading provider of ambulatory, continuous,
real-time outpatient management solutions for monitoring relevant
and timely clinical information regarding an individual's health.
CardioNet's initial efforts are focused on the diagnosis and
monitoring of cardiac arrhythmias, or heart rhythm disorders, with
a solution that it markets as Mobile Cardiac Outpatient Telemetry™
(MCOT™). More information can be found at
http://www.cardionet.com.
Forward-Looking Statements
This document includes certain forward-looking statements within
the meaning of the “Safe Harbor” provisions of the Private
Securities Litigation Reform Act of 1995 regarding, among other
things, our growth prospects, the prospects for our products and
our confidence in the Company’s future. These statements may be
identified by words such as “expect,” “may,” “anticipate,”
“possible,” “estimate,” “potential,” “intend,” “plan,” “believe,”
“forecast,” “promises” and other words and terms of similar
meaning. Such forward-looking statements are based on current
expectations and involve inherent risks and uncertainties,
including important factors that could delay, divert, or change any
of them, and could cause actual outcomes and results to differ
materially from current expectations. For further details and a
discussion of these and other risks and uncertainties, please see
our public filings with the Securities and Exchange Commission,
including our latest periodic reports on Form 10-K and 10-Q. We
undertake no obligation to publicly update any forward-looking
statement, whether as a result of new information, future events,
or otherwise.
HeartBeam (NASDAQ:BEAT)
Historical Stock Chart
From Jul 2024 to Aug 2024
HeartBeam (NASDAQ:BEAT)
Historical Stock Chart
From Aug 2023 to Aug 2024